Sepsis overviews or summaries of systematic reviews
BROWSE INFORMATION REPOSITORY
Summaries of systematic reviews
Cochrane Summary: Intravenous immunoglobulins for treating patients with severe sepsis and septic shock (2013)
Cochrane Summary: Intravenous immunoglobulins for treating patients with severe sepsis and septic shock (2013)
- Visit
Alejandria Marissa MLMA, D.; Dans Leonila, F.; Mantaring, I. I. I. Jacinto Blas
Alejandria Marissa MLMA, D.; Dans Leonila, F.; Mantaring, I. I. I. Jacinto Blas
Objective: For this updated Cochrane review, we searched the medical literature databases to January 2012. We included 43 randomized controlled trials (RCTs); 25 were RCTs of polyclonal intravenous immunoglobulins (IVIGs) with 17 in adults (1958 participants) and eight in newborn infants (3831 participants) including a large polyclonal IVIG trial on infants with sepsis that was published in 2011. The remaining 18 trials (a total of 13,413 participants) were of monoclonal antibodies. Published: 2013.
Cochrane Summary: Human recombinant activated protein C for severe sepsis and septic shock in adult and paediatric patients (2012)
Cochrane Summary: Human recombinant activated protein C for severe sepsis and septic shock in adult and paediatric patients (2012)
- Visit
Mart-Carvajal Arturo JS, Ivan; Gluud, Christian; Lathyris, Dimitrios; Cardona Andrs, Felipe
Mart-Carvajal Arturo JS, Ivan; Gluud, Christian; Lathyris, Dimitrios; Cardona...
Objective: In this updated Cochrane review we searched the databases until June 2012. We included six randomized clinical trials which involved 6781 people (6307 adult and 474 paediatric participants) with either a high or low risk of death. All trials had high risk of bias and were sponsored by the pharmaceutical industry (Eli Lilly). moreover, there is an increased risk of bleeding associated with its use. Published: 2012.
Cochrane Summary: Intravenous immunoglobulins for treating patients with severe sepsis and septic shock (2013)
Cochrane Summary: Intravenous immunoglobulins for treating patients with severe sepsis and septic shock (2013)
- Visit
Alejandria Marissa MLMA, D.; Dans Leonila, F.; Mantaring, I. I. I. Jacinto Blas
Alejandria Marissa MLMA, D.; Dans Leonila, F.; Mantaring, I. I. I. Jacinto Blas
Objective: For this updated Cochrane review, we searched the medical literature databases to January 2012. We included 43 randomized controlled trials (RCTs); 25 were RCTs of polyclonal intravenous immunoglobulins (IVIGs) with 17 in adults (1958 participants) and eight in newborn infants (3831 participants) including a large polyclonal IVIG trial on infants with sepsis that was published in 2011. The remaining 18 trials (a total of 13,413 participants) were of monoclonal antibodies. Published: 2013.
Cochrane Summary: Human recombinant activated protein C for severe sepsis and septic shock in adult and paediatric patients (2012)
Cochrane Summary: Human recombinant activated protein C for severe sepsis and septic shock in adult and paediatric patients (2012)
- Visit
Mart-Carvajal Arturo JS, Ivan; Gluud, Christian; Lathyris, Dimitrios; Cardona Andrs, Felipe
Mart-Carvajal Arturo JS, Ivan; Gluud, Christian; Lathyris, Dimitrios; Cardona...
Objective: In this updated Cochrane review we searched the databases until June 2012. We included six randomized clinical trials which involved 6781 people (6307 adult and 474 paediatric participants) with either a high or low risk of death. All trials had high risk of bias and were sponsored by the pharmaceutical industry (Eli Lilly). moreover, there is an increased risk of bleeding associated with its use. Published: 2012.
